SpyBiotech Appoints Seasoned Biotech Executive Mark Leuchtenberger as Chief Executive Officer

Louisa Rose

Research Associate

Louisa Rose

Louisa started working for SpyBiotech in January 2021 and is part of the adenoviral vector team developing vaccines targeting infectious diseases and cancer.

She developed her experience producing adenoviral vectors whilst working at the Jenner Institute, a department of the University of Oxford. Louisa spent several years there as part of a small viral vector core team and was involved in producing the first pre-clinical batch of the AstraZeneca Covid vaccine.

Her previous experiences were gained working at a few biotech companies including Gen-Probe, Oxford Immunotec and Orchid Cellmark. Louisa studied Human Biology at Oxford Brookes University.

Back to team

Read more about our pipeline and the diseases we are working to eradicate.

Our Pipeline